Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira

NCT03862716 · Completed

Last updated 2026-05-28

This clinical trial is testing whether a medication called IDegLira can help people with type 2 diabetes achieve remission without needing diabetes medications.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 159 people

Who can join Ages 30–80 · all sexes

Timeline Started 2019-04 · est. completion 2023-07

Where 8 sites · Canada

What this study is testing ClinicalTrials.gov NCT03862716 ↗

Description as written by the study sponsor.

The purpose of the study is to determine whether in patients with early type 2 diabetes, a short-term intensive metabolic intervention comprising IDegLira, metformin, and lifestyle approaches will be superior to standard diabetes therapy in achieving sustained diabetes remission.

Treatments tested

IDegLira also known as insulin degludec / liraglutide Drug

Dose is titrated to achieve fasting normoglycemia
insulin degludec Drug

In those who need additional insulin or who cannot tolerate IDegLira, insulin degludec will be used. Dose is titrated to achieve fasting normoglycemia.
Metformin Drug

Dose is titrated to 2000 mg per day or maximal tolerated dose
Lifestyle Therapy also known as diet and exercise Behavioral

Lifestyle intervention includes individualized dietary and exercise advice targeting at least 5% weight loss with frequent visits and coaching for goal reinforcement, behavior modification and problem-solving

Main thing measured	Proportion of participants achieving drug-free diabetes remission
Sponsor	Population Health Research Institute
Conditions studied	Type 2 Diabetes Mellitus
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03862716 ↗